New Auto-Injector lets MG patients Self-Dose at home
NCT ID NCT06471361
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether people with generalized myasthenia gravis (gMG) can safely and effectively use an auto-injector to give themselves the drug zilucoplan at home. Thirty-one adults who were already on a stable dose of zilucoplan took part. The main goal was to see if they could deliver the full dose correctly each time, with safety and tolerability also monitored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zilucoplan
What this could lead to
If successful, this could make it easier for people with generalized myasthenia gravis to self-administer their medication at home, improving convenience and independence.
What could go wrong
This is a small, completed Phase 3 study focused on device usability, not on proving the drug works. The results may not apply to all patients, and self-injection errors could still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dv0013 40605
Poznan, Poland
-
Dv0013 40609
Katowice, Poland
-
Dv0013 40759
Krakow, Poland
-
Dv0013 40760
Oxford, United Kingdom
-
Dv0013 50555
Austin, Texas, 78759, United States
-
Dv0013 50556
Chapel Hill, North Carolina, 27599, United States
-
Dv0013 50628
New Haven, Connecticut, 06511, United States
-
Dv0013 50634
Tampa, Florida, 33612, United States
-
Dv0013 50635
Columbus, Ohio, 43221, United States
-
Dv0013 50636
Greenfield, Wisconsin, 53228, United States
-
Dv0013 50648
Columbia, Missouri, 64212, United States